Gene: EZH2 ×
Source: ALL
Gene Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
Entrez Id: 2146
Gene Symbol: EZH2
EZH2 		0.080 Biomarker disease BEFREE EZH2 is an oncogene in non-Hodgkin lymphoma. 30885427 2019
Entrez Id: 2146
Gene Symbol: EZH2
EZH2 		0.080 Biomarker disease BEFREE Discovery of EBI-2511: A Highly Potent and Orally Active EZH2 Inhibitor for the Treatment of Non-Hodgkin's Lymphoma. 29456795 2018
Entrez Id: 2146
Gene Symbol: EZH2
EZH2 		0.080 Biomarker disease BEFREE Three EZH2 inhibitors: tazemetostat (EPZ-6438), GSK2816126 and CPI-1205 have moved into phase I/phase II clinical trials in patients with non-Hodgkin lymphoma and genetically defined solid tumors. 29473431 2018
Entrez Id: 2146
Gene Symbol: EZH2
EZH2 		0.080 Biomarker disease BEFREE Tazemetostat (EPZ-6438) is a selective inhibitor of the histone methyltransferase EZH2 and currently in clinical development for non-Hodgkin lymphoma and genetically defined tumors. 27555605 2017
Entrez Id: 2146
Gene Symbol: EZH2
EZH2 		0.080 GeneticVariation disease BEFREE Recently, EZH2 mutations have been reported at Y641, A677, and A687 in non-Hodgkin lymphoma. 25253781 2014
Entrez Id: 2146
Gene Symbol: EZH2
EZH2 		0.080 AlteredExpression disease BEFREE Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma. 24563539 2014
Entrez Id: 2146
Gene Symbol: EZH2
EZH2 		0.080 Biomarker disease BEFREE EZH2 inhibitor efficacy in non-Hodgkin's lymphoma does not require suppression of H3K27 monomethylation. 25457180 2014
Entrez Id: 2146
Gene Symbol: EZH2
EZH2 		0.080 GeneticVariation disease BEFREE Point mutations of EZH2 at Tyr641 and Ala677 occur in subpopulations of non-Hodgkin's lymphoma, where they drive H3K27 hypertrimethylation. 23023262 2012